SGS Expands Phase I Trial Bed Capacity
SGS Life Science Services, a division of the SGS Group, has expanded its Phase I units in Antwerp Stuivenberg hospital (Belgium) by adding 22 new hospitalization beds. The clinical pharmacology unit brings the total number of beds to 102 for Belgium, and brings SGS's global capacity to 184 beds.
More information is available in the official Media Information document (PDF 28 KB):
SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, Bioanalytical and QC testing. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can favourably impact client's drug development timelines and decision-making.
For more information, please visit our website, www.sgs.com/CRO"
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
